Valorization of an intestinal bacterium as a functional ingredient to prevent the development of metabolic syndrome and diabetes. – BIOPRED. AVI, Valencian Agency of Innovation. Ref: INNVA1/2021/32. 2021- 2023. Principal Investigator: Prof. Yolanda Sanz.
The aim of this project is to confirm the safety, stability and scalability of the production of a new human intestinal bacterium with the capacity to reduce the risk of developing metabolic syndrome and its progression towards chronic pathologies such as type 2 diabetes.
Objectives
- Evaluate the safety of the bacterium for consumption
- Optimization of the growth and up-scaling of the bacterial production
- Improvement of the stability of the product
- Establish tolerability and clinical efficacy of the bacterium
Strategy
- Toxicity studies to evaluate the safety of the bacterium in silico, in vitro and in vivo
- Optimize and up-scaling the production, using bioreactors of different sizes.
- Microencapsulation studies to improve stability of the bacterium in collaboration with AINIA
- Establishing tolerability and clinical efficacy in an exploratory study in humans
Impact
- Know-how in up-scaling cultures of anaerobic intestinal bacteria
- Help prevent the onset of metabolic syndrome and diabetes type 2 for at risk subjects.